AIB Seed Capital Fund
VC Fund
Dublin, Ireland
AIB Seed Capital Fund is a VC fund in Dublin focused on Software and Health Care. The AIB Seed Capital Fund was established in 2007 to provide venture capital for companies at the seed and early stages of development across a range of sectors throughout the Republic of Ireland. The Fund was established under the Enterprise Ireland Seed and Venture Capital Programme 2007-2012. The Fund has a total of €30m under management with AIB and Enterprise Ireland both committing €15m. It is managed by experienced managers with extensive expertise in making seed and early stage investments, adding value and facilitating business success. The Fund managers are empowered to make seed investments of up to approximately €500,000. Furthermore, the Fund has the capacity to make investments in later rounds to support the continued growth of investee companies. The Fund will be managed by Enterprise Equity Venture Capital and the Dublin Business Innovation Centre. This unique partnership brings together extensive regional and investment expertise. Enterprise Equity will evaluate and manage all investments outside the city and county of Dublin, as well as investments that require in excess of €250,000 from the fund within the city and county of Dublin. Dublin Business Innovation Centre (DBIC) will evaluate and manage all investments within the city and county of Dublin when the initial investment amount required from the Fund does not exceed €250,000.
- Total investments:
- 49
- Last investment:
- Lead investor:
- 18%
Last updated:
For AI agents: llms.txt
Industries AIB Seed Capital Fund invests in
SoftwareHealth CareMedicalMobileMedical Device
Stages AIB Seed Capital Fund invests in
SeedFunding RoundSeries AVenture - Series UnknownAngel
Countries AIB Seed Capital Fund invests in
IrelandUnited StatesJerseyUnited Kingdom
Round sizes
Seed $549k–$3.6MSeries A $1.1M–$8.1M
Contacts
| Name | Phone | Socials | |
|---|---|---|---|
Round size
- Seed
- $549k–$3.6M
- Series A
- $1.1M–$8.1M
Investment Focus
Industry
- Software 16 (33%)
- Health Care 9 (18%)
- Medical 5 (10%)
- Mobile 4 (8%)
- Medical Device 4 (8%)
Stage
- Seed 18 (37%)
- Funding Round 10 (20%)
- Series A 7 (14%)
- Venture - Series Unknown 4 (8%)
- Angel 1 (2%)
Country
- Ireland 30 (61%)
- United States 5 (10%)
- Jersey 1 (2%)
- United Kingdom 1 (2%)
Team
| Name | Title | Investments | Links | |
|---|---|---|---|---|
|
Bernard Byrne
CEO
|
CEO | Total investments: 0 | Find email |
Investments
| Company | Description | Round | Links |
|---|---|---|---|
| Offr is an open offer solution for buying and selling property, quickly, and transparently. It is an offer processing technology that sits on an agents branding to give their clients quality experience in the market. Through the small button on the agents site, they can manage custom offer sessions, schedule viewing, upload legal documents, andhold several transaction types, like binding sales to conditional sales, off-market sales, open offers, sealed bids, and auctions.All buyers are pre-qualified with a proof fund and identification. Preset conditions can be set by the agent per property which the buyer must complete before making an offer, completing these conditions shows the buyer has a higher intent to purchase.Offr was founded in 2018 and is headquartered in Dublin, Ireland. | $3.6M / Seed / Aug 20, 2020 | ||
| Metabolomic Diagnostics is a deep-tech company specialized in the development of novel biomarker based diagnostic solutions for complex diseases. The company has developed an effective pipeline to firstly identify diagnostic biomarker panels and then translate these panels into clinical assays ready for application in the clinical laboratory.Thispipeline combines the biomarker multiplexing capabilities of Mass Spectrometry, a powerful analytical technology, with the company’s own informatics and statistics solutions to deliver diagnostic innovation. This is reflected in Metabolomic Diagnostics’ strong and versatile IP portfolio of technical innovations and biomarkers.Our VisionMetabolomic Diagnostics’ primary vision is to develop a portfolio of diagnostic solutions which can determine, early in a woman’s pregnancy,her risk of developing major complications much later in her pregnancy and thus enabling personalized care, adapted to each woman’s individual needs. Pregnancy complications like preeclampsia, gestational diabetes, preterm birth, and in-uterine growth restriction, all have the potential to severely impact on the well-being of mother and child.The company’s innovative diagnostic solutions will assist clinicians in re-imagining how these conditions are managed: our novel risk assessment tools are specifically developed in conjunction with prenatal care providers to ensure they make a difference that really matters. This in turn will enable clinicians to improve pregnancy outcomes globally.Our solutions will empower pregnant women: accurate pregnancy risk information will allow a pregnant woman, in partnership with her care provider, to determine what prenatal care is best for her pregnancy. | $541.6K / Convertible Note / Apr 28, 2020 | ||
| Metabolomic Diagnostics is a deep-tech company specialized in the development of novel biomarker based diagnostic solutions for complex diseases. The company has developed an effective pipeline to firstly identify diagnostic biomarker panels and then translate these panels into clinical assays ready for application in the clinical laboratory.Thispipeline combines the biomarker multiplexing capabilities of Mass Spectrometry, a powerful analytical technology, with the company’s own informatics and statistics solutions to deliver diagnostic innovation. This is reflected in Metabolomic Diagnostics’ strong and versatile IP portfolio of technical innovations and biomarkers.Our VisionMetabolomic Diagnostics’ primary vision is to develop a portfolio of diagnostic solutions which can determine, early in a woman’s pregnancy,her risk of developing major complications much later in her pregnancy and thus enabling personalized care, adapted to each woman’s individual needs. Pregnancy complications like preeclampsia, gestational diabetes, preterm birth, and in-uterine growth restriction, all have the potential to severely impact on the well-being of mother and child.The company’s innovative diagnostic solutions will assist clinicians in re-imagining how these conditions are managed: our novel risk assessment tools are specifically developed in conjunction with prenatal care providers to ensure they make a difference that really matters. This in turn will enable clinicians to improve pregnancy outcomes globally.Our solutions will empower pregnant women: accurate pregnancy risk information will allow a pregnant woman, in partnership with her care provider, to determine what prenatal care is best for her pregnancy. | $2.4M / Grant / May 16, 2018 | ||
| Metabolomic Diagnostics is a deep-tech company specialized in the development of novel biomarker based diagnostic solutions for complex diseases. The company has developed an effective pipeline to firstly identify diagnostic biomarker panels and then translate these panels into clinical assays ready for application in the clinical laboratory.Thispipeline combines the biomarker multiplexing capabilities of Mass Spectrometry, a powerful analytical technology, with the company’s own informatics and statistics solutions to deliver diagnostic innovation. This is reflected in Metabolomic Diagnostics’ strong and versatile IP portfolio of technical innovations and biomarkers.Our VisionMetabolomic Diagnostics’ primary vision is to develop a portfolio of diagnostic solutions which can determine, early in a woman’s pregnancy,her risk of developing major complications much later in her pregnancy and thus enabling personalized care, adapted to each woman’s individual needs. Pregnancy complications like preeclampsia, gestational diabetes, preterm birth, and in-uterine growth restriction, all have the potential to severely impact on the well-being of mother and child.The company’s innovative diagnostic solutions will assist clinicians in re-imagining how these conditions are managed: our novel risk assessment tools are specifically developed in conjunction with prenatal care providers to ensure they make a difference that really matters. This in turn will enable clinicians to improve pregnancy outcomes globally.Our solutions will empower pregnant women: accurate pregnancy risk information will allow a pregnant woman, in partnership with her care provider, to determine what prenatal care is best for her pregnancy. | $1.2M / Venture - Series Unknown / Apr 06, 2018 | ||
| NewsWhip is the world's most comprehensive content discovery and analytics database. Their suite of products give customers the ability to predict which stories will be important today, and understand how to create successful content over the long term.NewsWhip serves over 500 of the world's leading publishers, brands and agencies,including: Reebok, the Washington Post, Conde Nast, Google, MasterCard, BuzzFeed, Time Inc., and more. NewsWhip Spike is their real-time, predictive content discovery dashboard — offering a one-stop view of what's important across both the web and 5 social networks. Spike is the only tool that discovers stories within 2 minutes of publishing, and predicts their spread across social.NewsWhip Analytics is a database of how audiences have engaged with stories across every social network over the long term. NewsWhip customers use Analytics to benchmark how they stack up against competitors and track engagement trends around events and seasons. | $6.4M / Series A / Feb 14, 2017 | ||
| SilverCloud Health provides immediate access to evidence-based and supported digital therapies. SilverCloud’s engagement has shown a three-fold increase in client/patient engagement and a three-fold decrease in client/patient program dropout when compared with current leading online therapeutic products. It was founded in 2011 andheadquartered in Boston, Massachusetts. | $8.1M / Series A / Jan 18, 2017 | ||
| Metabolomic Diagnostics is a deep-tech company specialized in the development of novel biomarker based diagnostic solutions for complex diseases. The company has developed an effective pipeline to firstly identify diagnostic biomarker panels and then translate these panels into clinical assays ready for application in the clinical laboratory.Thispipeline combines the biomarker multiplexing capabilities of Mass Spectrometry, a powerful analytical technology, with the company’s own informatics and statistics solutions to deliver diagnostic innovation. This is reflected in Metabolomic Diagnostics’ strong and versatile IP portfolio of technical innovations and biomarkers.Our VisionMetabolomic Diagnostics’ primary vision is to develop a portfolio of diagnostic solutions which can determine, early in a woman’s pregnancy,her risk of developing major complications much later in her pregnancy and thus enabling personalized care, adapted to each woman’s individual needs. Pregnancy complications like preeclampsia, gestational diabetes, preterm birth, and in-uterine growth restriction, all have the potential to severely impact on the well-being of mother and child.The company’s innovative diagnostic solutions will assist clinicians in re-imagining how these conditions are managed: our novel risk assessment tools are specifically developed in conjunction with prenatal care providers to ensure they make a difference that really matters. This in turn will enable clinicians to improve pregnancy outcomes globally.Our solutions will empower pregnant women: accurate pregnancy risk information will allow a pregnant woman, in partnership with her care provider, to determine what prenatal care is best for her pregnancy. | $1.9M / Venture - Series Unknown / Jun 16, 2016 | ||
| Davras' IoT Platform provides organizations with a flexible, secure and integrated platform to fully leverage current and future IoT deployments. Davra IOT platform is the only available IoT Platform on AWS SaaS Contracts (https://aws.amazon.com/marketplace/saas) giving it a very strong GTM strategy ahead of other IoTplatform vendors trying to attract System Integrator Partners.Davras' vision is to provide a complete Horizontal IoT AEP platform that allows our customers to define, build and bring to market vertical specific IoT applications. Davra Leads with Transportation VerticalThe ConnecThing™ IoT AEP platform is public cloud, private cloud (Openstack) based, simple to use application enablement platform that takes critical data from the network and any connected devices or sensors and publishes it through our IOT open API making it easy to build and run Internet of Things (IoT) applications. | $1.6M / Series A / Nov 19, 2015 | ||
| Benetel is based in Dublin, Ireland and was founded in 2001 by a team of engineers with many years wireless product development and production experience from companies such as Motorola, Lucent Technologies and Kenwood.Over the years, Benetel built a strong reputation globally for problem solving in RF and wireless design.Today Benetel hasan extensive customer base in the USA, UK, Brazil, Germany, France, Korea and Russia and has grown into a leading-edge solutions provider in the wireless marketplace. | $821.6K / Seed / Aug 03, 2015 | ||
| NewsWhip is the world's most comprehensive content discovery and analytics database. Their suite of products give customers the ability to predict which stories will be important today, and understand how to create successful content over the long term.NewsWhip serves over 500 of the world's leading publishers, brands and agencies,including: Reebok, the Washington Post, Conde Nast, Google, MasterCard, BuzzFeed, Time Inc., and more. NewsWhip Spike is their real-time, predictive content discovery dashboard — offering a one-stop view of what's important across both the web and 5 social networks. Spike is the only tool that discovers stories within 2 minutes of publishing, and predicts their spread across social.NewsWhip Analytics is a database of how audiences have engaged with stories across every social network over the long term. NewsWhip customers use Analytics to benchmark how they stack up against competitors and track engagement trends around events and seasons. | $1.6M / Venture - Series Unknown / May 28, 2015 | ||
| See all 49 investments → | |||
Co-Investors
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar industry
Similar stage
Similar country
Featured in Investor Lists
Recommended lists
SaaS Investors
118,083 investors
Software Investors
57,577 investors
Health Care Investors
48,825 investors
Medical Investors
21,329 investors
Mobile Investors
15,134 investors
Medical Device Investors
12,476 investors
SaaS VC Funds
72,248 investors
Software VC Funds
36,729 investors
Health Care VC Funds
36,610 investors
FAQ
What does AIB Seed Capital Fund invest in?
AIB Seed Capital Fund invests primarily in Software, Health Care and Medical startups, most often at Seed and Funding Round stage. Most of the 49 investments tracked by Shizune back companies in Ireland. The Investment Focus section breaks down every industry, stage and country in the portfolio.
What round sizes does AIB Seed Capital Fund invest in?
AIB Seed Capital Fund typically joins rounds of $549k–$3.6M at Seed and $1.1M–$8.1M at Series A. These are whole funding-round sizes, not AIB Seed Capital Fund's own check, which is rarely disclosed: the 10th–90th percentile of the confirmed public funding rounds AIB Seed Capital Fund took part in.
How do I contact AIB Seed Capital Fund?
Public channels for AIB Seed Capital Fund include X (Twitter) and the website linked on this profile. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.
Who are the partners at AIB Seed Capital Fund?
The team at AIB Seed Capital Fund includes Bernard Byrne (CEO). The Team section lists each member with their title, investment count and links.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Oct 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
